Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Beatrice Setnik, Kenneth W. Sommerville, Glenn C. Pixton & Lynn Webster. (2019) Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users. Current Medical Research and Opinion 35:3, pages 503-512.
Read now
Read now
Sahil Chaudhary & Peggy Compton. (2017) Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Substance Abuse 38:1, pages 95-104.
Read now
Read now
Tiffani D. Eisenhauer, Mike Matchett, Ralph Heasley, Terri Morton, Krishna Devarakonda, Michael Giuliani, Jim L. Young & Thomas Barrett. (2016) Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Development and Industrial Pharmacy 42:1, pages 157-165.
Read now
Read now
Lynn R. Webster, Michael J. Brennan, Louis M. Kwong, Richard Levandowski & Jeffrey A. Gudin. (2016) Opioid abuse-deterrent strategies: role of clinicians in acute pain management. Postgraduate Medicine 128:1, pages 76-84.
Read now
Read now
Wayne Wakeland, Alexandra Nielsen & Peter Geissert. (2015) Dynamic model of nonmedical opioid use trajectories and potential policy interventions. The American Journal of Drug and Alcohol Abuse 41:6, pages 508-518.
Read now
Read now
David J Mastropietro & Hossein Omidian. (2015) Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies. Expert Opinion on Pharmacotherapy 16:3, pages 305-323.
Read now
Read now
Michael E Schatman & Beth D Darnall. (2014) A practical and ethical solution to the opioid scheduling conundrum. Journal of Pain Research 7, pages 1-3.
Read now
Read now
Caroline Victorri-Vigneau, Cedric Collin, Catherine Messina-Gourlot, Christel Raffournier, Michel Mallaret, Jérôme Besse, Marie-Anne Courne, Nathalie Richard, Véronique Sébille & Philippe Arnaud. (2014) Designing a tool allowing for a standardized assessment of resistance to drug diversion. Expert Opinion on Drug Delivery 11:7, pages 995-1004.
Read now
Read now
Articles from other publishers (27)
M. Papadakos, M. Špaglová, M. Čuchorová & M. Hanko. (2023) A Multiple Unit Abuse-deterrent Dosage Form Based on Sodium Alginate. European Pharmaceutical Journal 0:0.
Crossref
Crossref
Dhwani Rana, Sagar Salave & Derajram Benival. (2022) Emerging Trends in Abuse-Deterrent Formulations: Technological Insights
and Regulatory Considerations. Current Drug Delivery 19:8, pages 846-859.
Crossref
Crossref
Mori Dhaval, Shweta Sharma, Kiran Dudhat & Jayant Chavda. (2020) Twin-Screw Extruder in Pharmaceutical Industry: History, Working Principle, Applications, and Marketed Products: an In-depth Review. Journal of Pharmaceutical Innovation 17:2, pages 294-318.
Crossref
Crossref
Parmita Phaugat, Suchitra Nishal & Rakhi Dhiman. (2022) Abuse-Deterrent Formulations in Constraining the Abuse Potential of Prescription
Medicines: A Myth or Truth. Current Drug Delivery 19:4, pages 466-478.
Crossref
Crossref
Benedikt Fischer. (2020) Some notes on the use, concept and socio-political framing of ‘stigma’ focusing on an opioid-related public health crisis. Substance Abuse Treatment, Prevention, and Policy 15:1.
Crossref
Crossref
Saikishore Meruva, Leyla Rezaei, Prajwal Thool & Maureen D. Donovan. (2020) Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets. AAPS PharmSciTech 21:7.
Crossref
Crossref
Ying Jiang, Kevin S. Murnane, Bruce E. Blough & Ajay K. Banga. (2020) Transdermal Delivery of the Free Base of 3-Fluoroamphetamine: In Vitro Skin Permeation and Irritation Potential. AAPS PharmSciTech 21:3.
Crossref
Crossref
Xin Feng, Ahmed Zidan, Nahid S. Kamal, Xiaoming Xu, Dajun Sun, Ross Walenga, Heather Boyce, Celia N. Cruz & Muhammad Ashraf. (2020) Assessing Drug Release from Manipulated Abuse Deterrent
Formulations. AAPS PharmSciTech 21:2.
Crossref
Crossref
Keith Humphreys & Harold A. Pollack. 2020. The Palgrave Handbook of American Mental Health Policy. The Palgrave Handbook of American Mental Health Policy
259
295
.
Jan Kozak, Miloslava Rabiskova & Alf Lamprecht. (2019) Silk Fibroin as a Novel Alcohol-Resistant Excipient for Sustained-Release Tablet Formulation. AAPS PharmSciTech 20:7.
Crossref
Crossref
Saikishore Meruva & Maureen D. Donovan. (2019) Effects of Drug-Polymer Interactions on Tablet Properties During
the Development of Abuse-Deterrent Dosage Forms. AAPS PharmSciTech 20:3.
Crossref
Crossref
Benedikt Fischer, Lenka Vojtila & Paul Kurdyak. (2017) ‘Delisting’ OxyContin® to reduce prescription opioid-related harms in Ontario (Canada)-gauging effects 5 years later. Pharmacoepidemiology and Drug Safety 26:9, pages 1040-1043.
Crossref
Crossref
D. Mastropietro, K. Park & H. Omidian. 2017. Comprehensive Biomaterials II. Comprehensive Biomaterials II
430
444
.
Beatrice Setnik, Almasa Bass, Candace Bramson, Naama Levy-Cooperman, Bimal Malhotra, Kyle Matschke, Pierre Geoffroy, Kenneth W. Sommerville & Gernot Wolfram. (2016) Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users. Pain Medicine, pages pnw178.
Crossref
Crossref
Julien Maincent & Feng Zhang. (2016) Recent advances in abuse-deterrent technologies for the delivery of opioids. International Journal of Pharmaceutics 510:1, pages 57-72.
Crossref
Crossref
Nicole Jedinger, Simone Schrank, Johannes M. Fischer, Karlheinz Breinhälter, Johannes Khinast & Eva Roblegg. (2015) Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating. AAPS PharmSciTech 17:1, pages 68-77.
Crossref
Crossref
Benedikt Fischer, Cayley Russell, Yoko Murphy & Paul Kurdyak. (2015) Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?. Pharmacoepidemiology and Drug Safety 24:12, pages 1334-1336.
Crossref
Crossref
Richard L. Rauck, Martin E. Hale, Almasa Bass, Candace Bramson, Glenn Pixton, Jacquelyn G. Wilson, Beatrice Setnik, Paul Meisner, Kenneth W. Sommerville, Bimal K. Malhotra & Gernot Wolfram. (2015) A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. Pain 156:9, pages 1660-1669.
Crossref
Crossref
Bing Cai, Håkan Engqvist & Susanne Bredenberg. (2015) Development and evaluation of a tampering resistant transdermal fentanyl patch. International Journal of Pharmaceutics 488:1-2, pages 102-107.
Crossref
Crossref
Bimal K. Malhotra, Kyle Matschke, Qiang Wang, Candace Bramson & Joanne Salageanu. (2015) Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02). Clinical Drug Investigation 35:4, pages 267-274.
Crossref
Crossref
N. Jedinger, J. Khinast & E. Roblegg. (2014) The design of controlled-release formulations resistant to alcohol-induced dose dumping – A review. European Journal of Pharmaceutics and Biopharmaceutics 87:2, pages 217-226.
Crossref
Crossref
David J. Mastropietro & Hossein Omidian. (2014) ChemInform Abstract: Current Approaches in Tamper‐Resistant and Abuse‐Deterrent Formulations. ChemInform 45:16.
Crossref
Crossref
Bing Cai, Håkan Engqvist & Susanne Bredenberg. (2014) Evaluation of the resistance of a geopolymer-based drug delivery system to tampering. International Journal of Pharmaceutics 465:1-2, pages 169-174.
Crossref
Crossref
Steven D. Passik. (2014) Tamper-Resistant Opioid Formulations in the Treatment of Acute Pain. Advances in Therapy 31:3, pages 264-275.
Crossref
Crossref
Sindhuri Maddineni, Sunil Kumar Battu, Joe Morott, Majumdar Soumyajit & Michael A Repka. (2014) Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments. Journal of Pharmacy and Pharmacology 66:2, pages 309-322.
Crossref
Crossref
Esther Papaseit, Clara Pérez-Mañá, Marta Torrens & Magí Farré. (2013) Reacciones adversas de medicamentos relacionadas con el abuso y formas farmacéuticas disuasorias. Medicina Clínica 141:10, pages 454-458.
Crossref
Crossref
Suzanne K. Vosburg, Jermaine D. Jones, Jeanne M. Manubay, Judy B. Ashworth, Douglas Y. Shapiro & Sandra D. Comer. (2013)
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin
®
(non-TRF) in prescription opioid abusers
. Addiction 108:6, pages 1095-1106.
Crossref
Crossref